US Patent Issued to Hebei Senlang Biotechnology on April 21 for "Method for producing t cells modified by chimeric antigen receptor" (Chinese Inventors)

ALEXANDRIA, Va., April 21 -- United States Patent no. 12,606,831, issued on April 21, was assigned to Hebei Senlang Biotechnology Co. Ltd. (Hebei, China).

"Method for producing t cells modified by chimeric antigen receptor" was invented by Jianqiang Li (Hebei, China), Qinglong Wang (Hebei, China) and Lin Wang (Hebei, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method for producing GammaDelta T cells modified by a chimeric antigen receptor, comprising: transfecting K562 cells with shFPPS targeted to FPP synthase by means of a lentiviral vector, such that the expression of FPPS in the K562 cells is lowered and a K562-shFPPS cell line with reduced FPPS expression is constructed; adding the K562-shFPP...